Category: Markets
Published: 2026-06-30T14:22:45.000Z
The U.S. FDA has chosen seven companies, including Eli Lilly and Regeneron Pharmaceuticals, for its PreCheck Pilot Program. This initiative aims to accelerate the review process for new domestic pharmaceutical manufacturing facilities by allowing regulators to assess sites during construction, potentially saving companies up to 14 months in approval time. The selected facilities will produce a variety of products, such as GLP-1 ingredients, biologics, and gene therapies, to address drug supply gaps and expand patient access in areas of unmet medical need.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.